Agenda BJCN-MORE 2023
Management of Esophageal and Gastroesophageal Junction Carcinoma
Tele-oncology and BJCN Cluster Interactions
9 November
10 November
11 November
12 November
9 November
Official opening
Annual Award BJCN-MORÉ – for contribution to Bulgarian clinical oncology
Symposium BMS (Swixx BioPharma)
Symposium Merck
Symposium Varia
18:25 – 18:45 Amgen Presentation
18:45 – 19:05 Eli Lilly Presentation
19:05 – 19:25 Novartis Presentation
19:25 – 19:45 Johnson & Johnson Presentation
18:45 – 19:05 Eli Lilly Presentation
19:05 – 19:25 Novartis Presentation
19:25 – 19:45 Johnson & Johnson Presentation
Welcome dinner
10 November
FIRST PLENARY SESSION
Pretherapeutic and diagnostic issues in esophageal and gastroesophageal
junction carcinoma (GJC)
Chairman: Draga Toncheva
08:00 – 08:15 Update on the GRADE approach: PICO(S&T), assessment of inconsistencies (I2 ) and use of ICEMAN
Dimitar Kalev
08:20 – 08:40 Genetic architecture of esophageal carcinoma
Draga Toncheva
08:45 – 09:05 Liquid biopsy as a method of diagnosis, prognosis and prediction in esophageal carcinoma and GJC
Milka Georgieva
09:10 – 09:30 Value of screening endoscopy and target population in esophageal carcinoma and GJC: how early detection and prevention strategies can be improved
Petko Karagyozov, Zornica Gorcheva
09:35 – 09:55 Cellular and molecular drivers in Barrett’s esophagus and adenocarcinoma
Svitlana Bachurska
10:00 – 10:20 Clinical significance of the microbiome in upper gastrointestinal carcinomas
Milka Georgieva, Marchela Koleva
10:25 – 10:45 Benefits, pitfalls, and artificial intelligence (AI) in hybrid imaging of esophageal carcinoma
E. Piperkova, Lidia Chavdarova, I. Kostadinova
Chairman: Draga Toncheva
08:00 – 08:15 Update on the GRADE approach: PICO(S&T), assessment of inconsistencies (I2 ) and use of ICEMAN
Dimitar Kalev
08:20 – 08:40 Genetic architecture of esophageal carcinoma
Draga Toncheva
08:45 – 09:05 Liquid biopsy as a method of diagnosis, prognosis and prediction in esophageal carcinoma and GJC
Milka Georgieva
09:10 – 09:30 Value of screening endoscopy and target population in esophageal carcinoma and GJC: how early detection and prevention strategies can be improved
Petko Karagyozov, Zornica Gorcheva
09:35 – 09:55 Cellular and molecular drivers in Barrett’s esophagus and adenocarcinoma
Svitlana Bachurska
10:00 – 10:20 Clinical significance of the microbiome in upper gastrointestinal carcinomas
Milka Georgieva, Marchela Koleva
10:25 – 10:45 Benefits, pitfalls, and artificial intelligence (AI) in hybrid imaging of esophageal carcinoma
E. Piperkova, Lidia Chavdarova, I. Kostadinova
Coffee break
SECOND PLENARY SESSION
Surgical strategies in esophageal and gastroesophageal junction carcinoma
Chairman: Nikola Vladov
11:10 – 11:30 Endoscopic control of early esophageal carcinoma and GJC – pitfalls and outcomes
Alexander Katzarov
11:35 – 11:55 Traditions and modifications in theIvor Lewis esophagectomy technique
Nikolay Belev
12:00 – 12:20 Ivor Lewis steps in minimally invasive and robotic esophagectomy
Tsvetan Minchev
12:25 – 12:45 Transhiatal and left sided thoracoabdominal techniques for esophagectomy
Daniel Kostov
12:50 – 13:10 Protocols for three-fieldMcKeown esophagectomy
Tsvetan Minchev
13:15 – 13:35 Liver metastases from esophageal carcinoma – is there a role for surgical resection
Radoslav Kostadinov, Cvetan Trichkov, Vasil Mihailov, Nikola Vladov
Chairman: Nikola Vladov
11:10 – 11:30 Endoscopic control of early esophageal carcinoma and GJC – pitfalls and outcomes
Alexander Katzarov
11:35 – 11:55 Traditions and modifications in theIvor Lewis esophagectomy technique
Nikolay Belev
12:00 – 12:20 Ivor Lewis steps in minimally invasive and robotic esophagectomy
Tsvetan Minchev
12:25 – 12:45 Transhiatal and left sided thoracoabdominal techniques for esophagectomy
Daniel Kostov
12:50 – 13:10 Protocols for three-fieldMcKeown esophagectomy
Tsvetan Minchev
13:15 – 13:35 Liver metastases from esophageal carcinoma – is there a role for surgical resection
Radoslav Kostadinov, Cvetan Trichkov, Vasil Mihailov, Nikola Vladov
Lunch
THIRD PLENARY SESSION
Problems of perioperative approaches in esophageal and gastroesophageal
junction carcinoma
Chairman: Vesela Ivanova
14:30 – 14:50 Classification of pathologic response from neoadjuvant therapy in esophageal carcinoma and GJC
Ivan Ivanov
14:55 – 15:15 Imaging biomarkers in the treatment of esophageal carcinoma
Vesela Stoynova, Nataliya Mladenova, Galina Kirova
15:20 – 15:40 Prediction of pCR and detection of residual disease in neoadjuvant chemoradiotherapy for esophageal carcinoma
Vesela Ivanova
15:45 – 16:05 The unusual patient with ypT0N+ esophageal carcinoma – what’s next
Nataliya Chilingirova
Chairman: Vesela Ivanova
14:30 – 14:50 Classification of pathologic response from neoadjuvant therapy in esophageal carcinoma and GJC
Ivan Ivanov
14:55 – 15:15 Imaging biomarkers in the treatment of esophageal carcinoma
Vesela Stoynova, Nataliya Mladenova, Galina Kirova
15:20 – 15:40 Prediction of pCR and detection of residual disease in neoadjuvant chemoradiotherapy for esophageal carcinoma
Vesela Ivanova
15:45 – 16:05 The unusual patient with ypT0N+ esophageal carcinoma – what’s next
Nataliya Chilingirova
Coffee break
Symposium MSD
DISCUSSION SESSION
Expert discussion Pros/Cons
Модератор: Tatiana Hadjieva
17:35 – 17:55 Management of T1b esophageal carcinoma: endoscopic resection versus esophagectomy
Petko Karagyozov vsNikolay Belev
17:55 – 18:15 Neoadjuvant therapy in esophageal adenocarcinoma and GJC: chemotherapy versus radiochemotherapy
Marchela Koleva vs Tatiana Hadjieva
18:15 – 18:35 Treatment of locally advanced esophageal squamous cell carcinoma: definitive radiochemotherapy versus neoadjuvant radiochemotherapy followed by surgery
Kaloyan Yordanov vs Kamen Nedev
Модератор: Tatiana Hadjieva
17:35 – 17:55 Management of T1b esophageal carcinoma: endoscopic resection versus esophagectomy
Petko Karagyozov vsNikolay Belev
17:55 – 18:15 Neoadjuvant therapy in esophageal adenocarcinoma and GJC: chemotherapy versus radiochemotherapy
Marchela Koleva vs Tatiana Hadjieva
18:15 – 18:35 Treatment of locally advanced esophageal squamous cell carcinoma: definitive radiochemotherapy versus neoadjuvant radiochemotherapy followed by surgery
Kaloyan Yordanov vs Kamen Nedev
Symposium AstraZeneca
Dinner
11 November
FOURTH PLENARY SESSION
Systemic, radiotherapy and palliative strategies in esophageal and
gastroesophageal junction carcinoma
Chairman: Margarita Genova
08:00 – 08:20 Sensitivity of hematologic markers in patients receiving therapy for esophageal carcinoma
Margarita Genova, Gueorgui Balatzenco
08:25 – 08:45 Targets in systemic therapy in esophageal carcinoma and GJC
Radoslav Mangaldziev
08:50 – 09:10 Integration of immunotherapy across all lines of treatment in esophageal carcinoma and GJC – prediction with PD-L1, MSI, and TMB
Asya Konsoulova
09:15 – 09:35 Chemoradiation in oligometastatic disease from esophageal carcinoma
Tatiana Hadjieva, Marchela Koleva
09:40 – 10:00 Effect of early nutritional support on clinical outcomes in esophageal carcinoma
Nikolay Yordanov
Chairman: Margarita Genova
08:00 – 08:20 Sensitivity of hematologic markers in patients receiving therapy for esophageal carcinoma
Margarita Genova, Gueorgui Balatzenco
08:25 – 08:45 Targets in systemic therapy in esophageal carcinoma and GJC
Radoslav Mangaldziev
08:50 – 09:10 Integration of immunotherapy across all lines of treatment in esophageal carcinoma and GJC – prediction with PD-L1, MSI, and TMB
Asya Konsoulova
09:15 – 09:35 Chemoradiation in oligometastatic disease from esophageal carcinoma
Tatiana Hadjieva, Marchela Koleva
09:40 – 10:00 Effect of early nutritional support on clinical outcomes in esophageal carcinoma
Nikolay Yordanov
Comprehensive genomic profiling
Coffee break
Symposium Pierre Fabre
Symposium Pfizer
Lunch
Symposium Roche
FIRST BJCN JOINT SESSION
Integrative Oncology
Chairman: Petko Zagorchev
14:45 – 15:00 Possibilities of homeopathy in the integrative approach in oncological patients
Dr J-L Bagot
15:05 – 15:20 My experience in complementary treatment in cancer patients
Petko Zagorchev
15:25 – 15:40 Possibilities of homeopathy to support the cancer patient in the general practitioner’s office
Ivan Enev
Chairman: Petko Zagorchev
14:45 – 15:00 Possibilities of homeopathy in the integrative approach in oncological patients
Dr J-L Bagot
15:05 – 15:20 My experience in complementary treatment in cancer patients
Petko Zagorchev
15:25 – 15:40 Possibilities of homeopathy to support the cancer patient in the general practitioner’s office
Ivan Enev
SECOND BJCN JOINT SESSION
Cluster interaction potentials in BJCN: multipliers, mutual benefits and
ecosystem effects
Moderator: Dimitar Kalev
15:45 – 15:50 Welcome and introductions
15:50 – 16:05 Projects with the participation of BJCN – presentation with perspectives
Ivaylo Petrov
16:05 – 16:20 BJCN programs for continuing medical education in oncology and oncohematology
Margarita Genova
16:20 – 16:25 Discussion
Moderator: Dimitar Kalev
15:45 – 15:50 Welcome and introductions
15:50 – 16:05 Projects with the participation of BJCN – presentation with perspectives
Ivaylo Petrov
16:05 – 16:20 BJCN programs for continuing medical education in oncology and oncohematology
Margarita Genova
16:20 – 16:25 Discussion
Coffee break
THIRD BJCN JOINT SESSION
Mission 3.0. Tele-oncology in the social triangle – research, technologies, and
policies
Part I: Keynote panel
Moderators: Ivana Cattaneo
16:50 – 17:05 TBC
Yasmin Fonseca
Agency for Clinical Research and Biomedical Innovation (AICIB), Portugal
17:05 – 17:20 TBC
Dr Marius Geantă, Bianca Cucoș
Centre for Innovation in Medicine (InoMed), Romania
17:20 – 17:35 TBC
Organisation of European Cancer Institutes (OECI) [TBC]
17:35 – 17:50 TBC
Tugce Schmitt, Katharina Habimana
Strengthening eHealth for Cancer Prevention and Care (eCAN Joint Action) [TBC]
17:50 – 18:05 Digital solutions for monitoring patient symptoms and adverse drug events
Prof. Galina Velikova
University of Leeds, UK
18:05 – 18:10 Concluding remarks
Part II: Discussion panel
Moderators: Alexander Simidchiev
18:15 – 19:40 Action-oriented discussion
With representatives from: Ministry of Health, Parliamentary Health Commission, Municipality of Varna, Bulgarian Cluster for Digital Solutions and Innovations in Health Care, National Patient Organization, Junior Achievement Bulgaria, Law Office Murgova and Partners, USBALO, BJCN
19:40 – 19:45 Concluding remarks
Part I: Keynote panel
Moderators: Ivana Cattaneo
European Federation of Pharmaceutical Industries and Associations
(EFPIA)
Ivaylo Petrov, BJCN
16:50 – 17:05 TBC
Yasmin Fonseca
Agency for Clinical Research and Biomedical Innovation (AICIB), Portugal
17:05 – 17:20 TBC
Dr Marius Geantă, Bianca Cucoș
Centre for Innovation in Medicine (InoMed), Romania
17:20 – 17:35 TBC
Organisation of European Cancer Institutes (OECI) [TBC]
17:35 – 17:50 TBC
Tugce Schmitt, Katharina Habimana
Strengthening eHealth for Cancer Prevention and Care (eCAN Joint Action) [TBC]
17:50 – 18:05 Digital solutions for monitoring patient symptoms and adverse drug events
Prof. Galina Velikova
University of Leeds, UK
18:05 – 18:10 Concluding remarks
Part II: Discussion panel
Moderators: Alexander Simidchiev
Dimitar Kalev
18:10 – 18:15 Welcome and introductions18:15 – 19:40 Action-oriented discussion
With representatives from: Ministry of Health, Parliamentary Health Commission, Municipality of Varna, Bulgarian Cluster for Digital Solutions and Innovations in Health Care, National Patient Organization, Junior Achievement Bulgaria, Law Office Murgova and Partners, USBALO, BJCN
19:40 – 19:45 Concluding remarks
Dinner
12 November
FOURTH BJCN JOINT SESSION
Health technologies panorama in Bulgarian oncology
Moderator: Ivan Lekushev
Moderator: Ivan Lekushev
JOINT BJCN ROUND TABLE
Cluster interaction in BJCN – capacity building
Moderator: Dimitar Kalev
With the participation of representatives from all organizations that are members of BJCN
Moderator: Dimitar Kalev
With the participation of representatives from all organizations that are members of BJCN